Navigation Links
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
Date:5/18/2012

MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL.  Actavis believes this is the first generic Requip® XL available in the US.  Distribution of the product has commenced.  

Requip® XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4 million for the 12 months ending December 31, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The launch of Ropinirole Extended-Release Tablets showcases  Actavis' commitment in bringing new products to market to benefit both patients and payors. We are proud to play a part in lowering healthcare costs through the introduction of quality generic products."

 

Inquiries
David Myers, Jr.
Senior Manager, Products & Communications
Tel: (973)993-4503
E-mail: dmyers@actavis.com

About Actavis:
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Requip® XL is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

 


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. Actavis Launches Generic Version of Flomax(R) In The U.S.
3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
4. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
5. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
6. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
7. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
8. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
11. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
(Date:3/24/2017)... , March 24, 2017  GenomeDx Biosciences today announced ... Database) and Decipher® Prostate Cancer Classifier tests will be ... of Urology (EAU) Congress held March 24 to 28, ... Annual EAU Congress is Europe,s ... research in the urological field. The abstract ...
(Date:3/24/2017)...  HealthMine surveys with 9,250 insured consumers fielded from ... members want help from their plans in five key ... health, 2) help closing gaps in care, 3) better ... 5) relevant, real-time guidance. Meeting these needs is essential ... A Reason to Stay Engaged in ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... to the military at the same time by providing Prehospital Trauma Life Support ... PHTLS is the world’s premier prehospital trauma education developed in cooperation with the ...
(Date:3/24/2017)... ... , ... Digital Scientists, a software innovation lab specializing in web design and ... South Carolina location. The lab has set up shop at the renowned NEXT ... South Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ ...
(Date:3/24/2017)... San Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... a new clinic which can be found at 9618 Huebner Road. The clinic is ... Thobaben, PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher Anahata ... and Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous ... spiritual journey during the Summer Solstice will also be her final international retreat, ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... announce that they are now offering treatments for sleep apnea and TMJ at ... offices. Sleep apnea , specifically the obstructive type, is increasingly being treated ...
Breaking Medicine News(10 mins):